NeoTract Announces UroLift System Now Available to Millions More Americans

Guía de Regalos

Minimally Invasive Treatment for Enlarged Prostate Now Available to
Most Medicare, Medicaid and Commercial Insurance Beneficiaries

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet
needs in the field of urology, today announced the recent addition of
several new insurance positive coverage decisions to expand access to
the UroLift® System as a covered benefit for many more men
across the United States, including Medicare, Medicaid and commercial
insurance beneficiaries.

“Thanks to the rigorous clinical data, widespread adoption, and
enthusiastic support from the urologic community, the UroLift prostatic
urethral lift is a proven treatment option for millions of men suffering
from enlarged prostate issues,” said Dave Amerson, president and CEO of
NeoTract, Inc. “We are delighted that commercial insurers and
independent networks as well as Medicare and Medicaid have acknowledged
that the UroLift System offers an early treatment option that is
minimally invasive and cost-effective for men that are not well served
by medical therapy.”

Recently, a positive coverage decision was issued by Medicare
administrative contractor National Government Services, Inc. (NGS), for
beneficiaries in the states of Connecticut, Illinois, Maine,
Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont
and Wisconsin. The UroLift System was also made available to
beneficiaries of independent networks, such as Kaiser Permanente and
SelectHealth, as well as numerous Blue Cross Blue Shield plans, such as
CareFirst, Highmark, Louisiana, Nebraska and South Carolina.

Benign prostatic hyperplasia (BPH), also known as enlarged prostate,
affects more than 37 million men in the United States alone. Much more
prevalent than prostate cancer, BPH occurs when the prostate gland that
surrounds the male urethra becomes enlarged with advancing age and
begins to obstruct the urinary system.

“We are pleased with the support for the clinical and economic value of
UroLift,” added Amerson. “We are committed to ensuring as many men as
possible have access to the UroLift System.”

The UroLift System provides a unique approach to treating BPH that lifts
and holds the enlarged prostate tissue out of the way so it no longer
blocks the urethra. UroLift is the only BPH procedure that does not
require cutting, heating or removal of the prostate tissue.

Symptoms of BPH often include sleepless nights and urinary problems, and
can cause loss of productivity, depression and decreased quality of
life. Medication is often the first-line therapy for enlarged prostate,
but relief can be inadequate and temporary. Side effects of medication
treatment can include sexual dysfunction, dizziness and headaches,
prompting many patients to quit using the drugs. For these patients, the
classic alternative is surgery that cuts, burns or ablates prostate
tissue to open the blocked urethra. While current surgical options can
be very effective in relieving symptoms, they can also leave patients
with permanent side effects such as urinary incontinence, erectile
dysfunction and retrograde ejaculation (dry orgasm).

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during a
minimally invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating, or
removing prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged prostate
receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.
Patients also experienced a significant improvement in quality of life.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System is available in the U.S.,
Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.UroLift.com
or www.NeoTract.com.

Contacts

For NeoTract, Inc.:
Nicole Osmer, 650-454-0504
nicole@nicoleosmer.com